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Summary
Background: Previous studies have reached conflicting conclusions regarding the
efficacy of mesalazine in the prevention of recurrent diverticulitis.
Aim: To investigate the efficacy and safety of mesalazine granules in the prevention
of recurrence of diverticulitis after acute uncomplicated diverticulitis.
Methods: Two phase 3, randomised, placebo-controlled, double-blind multicentre tri-
als (SAG-37 and SAG-51) investigated mesalazine granules in patients with prior epi-
sodes (<6 months) of uncomplicated left-sided diverticulitis. Patients were
randomised to receive either 3 g mesalazine once daily or placebo (SAG-37, n=345) or
to receive either 1.5 g mesalazine once daily, 3 g once daily or placebo for 96 weeks
(SAG-51, n=330). The primary endpoint was the proportion of recurrence-free
patients during 48 weeks (SAG-37 and SAG-51) or 96 weeks (SAG-51) of treatment.
Results: Mesalazine did not increase the proportion of recurrence-free patients over
48 or 96 weeks compared to placebo. In SAG-37, the proportion of recurrence-free
patients during 48 weeks was 67.9% with mesalazine and 74.4% with placebo
(P=.226). In SAG-51, the proportion of recurrence-free patients over 48 weeks was
46.0% with 1.5 g mesalazine, 52.0% with 3 g mesalazine and 58.0% with placebo
(P=.860 for 3 g mesalazine vs placebo) and over 96 weeks 6.9%, 9.8% and 23.1%
respectively (P=.980 for 3 g mesalazine vs placebo). Patients with only one divertic-
ulitis episode in the year prior to study entry had a lower recurrence risk compared
to >1 episode. Safety data revealed no new adverse events.
Conclusion: Mesalazine was not superior to placebo in preventing recurrence of
diverticulitis.
The Handling Editor for this article was Dr Colin Howden, and it was accepted for publication after full peer-review.
For affiliations of the authors, see Appendix 1
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2017 The Authors. Alimentary Pharmacology and Therapeutics published by John Wiley & Sons Ltd
Received: 20 February 2017 | First decision: 27 February 2017 | Accepted: 27 April 2017
DOI: 10.1111/apt.14152
282 | wileyonlinelibrary.com/journal/apt Aliment Pharmacol Ther. 2017;46:282–291.
1 | INTRODUCTION
Diverticula are herniations of the intestinal mucosa through the
bowel wall. Diverticula are often asymptomatic, then termed diver-
ticulosis, but can be associated with abdominal pain, bloating and
changes in bowel habits, in which case they are referred to in a
more general way as diverticular disease (DD).1,2 These symptoms
can represent symptomatic uncomplicated diverticular disease
(SUDD), in which the abdominal symptoms are attributed to divertic-
ula, but in the absence of significant inflammation.1,2 SUDD is a
pathogenetically ill-defined entity with a heterogeneous disease pat-
tern, often difficult to differentiate from irritable bowel syndrome.3
In contrast to SUDD, acute diverticulitis is defined by active inflam-
mation of diverticula. Diverticulitis can be either uncomplicated or
complicated. Uncomplicated diverticulitis shows colonic wall thicken-
ing and peridiverticulitis by cross-sectional imaging, while compli-
cated diverticulitis is associated with abscesses or fistula or
obstruction or perforation. Once an acute episode of uncomplicated
diverticulitis has resolved, 13% to 36% of patients experience a
recurrent episode of acute diverticulitis.4 Considering patients with
complicated diverticulitis, the majority of these patients present with
complicated diverticulitis as their first episode and 47% have recur-
rent diverticulitis.5 Perforation, the most dangerous complication,
happens nearly always during the first attack of diverticulitis.5 Com-
plicated diverticulitis was only described in 5% of the patients after
an initial uncomplicated episode in a 8 year follow-up,6 but about
13% of patients with prior episodes required hospital admissions for
the treatment of the recurrent episode.7 Therefore, recurrent epi-
sodes of acute diverticulitis not only dramatically decrease the
patient quality of life, but also substantially increase the burden on
health care resources.2 In addition, as the risk of recurrence seems
to increase with each episode,8 an efficacious prevention strategy is
desirable. However, largely due to a lack of blinded, randomised,
controlled trials, recommendations for the preventive treatment of
recurrent acute diverticulitis are seldom based on adequate scientific
evidence and are often inconsistent.2
As the medical management of inflammatory bowel disease
such as ulcerative colitis has classically been based on aminosalicy-
lates including mesalazine, a number of studies have also evaluated
the role of mesalazine (also known as mesalamine or 5-ASA [5-ami-
nosalicylic acid]) in the management of DD. Indeed, benefits of
mesalazine for the treatment of SUDD have been reported.9-15
Some randomised controlled trials have also found beneficial
effects of mesalazine in reducing symptoms of patients with a his-
tory of acute uncomplicated diverticulitis, but showed no impact on
the recurrence rate.16,17 Furthermore, two recent placebo-con-
trolled trials investigating the efficacy of mesalazine for the preven-
tion of acute diverticulitis recurrence demonstrated negative
results.18 Although these studies had clear diagnostic criteria on
recurrence, they have been criticised for ignoring the course of glo-
bal symptoms throughout the study period.19 Therefore, to resolve
these inconsistent conclusions, further well-designed studies are
urgently needed.20
Here, we report the findings of two multicentre, international,
randomised, double-blind studies undertaken to determine whether
mesalazine is superior to placebo in preventing diverticulitis recur-
rence after acute uncomplicated diverticulitis, and to evaluate
whether there are subgroups of patients who may respond to pre-
ventive anti-inflammatory treatment.
2 | METHODS
2.1 | Study design and conduct
Two phase 3, multicentre, randomised, double-blind, placebo-con-
trolled studies (SAG-37 and SAG-51) were conducted at specialised
gastroenterology centres (NCT00695643, NCT01038739). The SAG-
37 study was performed from 2008 to 2011 at 57 centres in 11
countries; SAG-51 was undertaken from 2010 to 2013 at 74 centres
in nine countries. Both studies used an adaptive, multistage group
sequential design. The SAG-51 study was stopped due to futility
after a planned interim analysis, following a recommendation from
the Independent Data Monitoring Committee, with immediate with-
drawal of treatment and premature study termination in all patients
who had not yet completed the study.
The study protocols were approved by the institutional review
board at each centre and written informed consent was obtained
from all participants.
2.2 | Patients
Patients were eligible for the study if (1) they were between 30 and
80 years old (SAG-51) or 40-80 years old (SAG-37), (2) they had a
prior diagnosis of left-sided uncomplicated acute diverticulitis con-
firmed by ultrasonography or computed tomography (CT) with at
least one diverticulum in the left colon (In SAG-51, abdominal CT
was performed to depict the thickness of the colonic wall as well as
signs of inflammation around the diverticula. Scans were analysed by
central reading. In SAG-37, assessment of colonic wall thickening by
ultrasonography or CT was required.), (3) the prior episode of left-
sided uncomplicated diverticulitis was within the preceding 6 months
and has been brought to clinical remission with antibiotics and/or
dietary modification, documented by medical records, (4) they had
≥3 of the following symptoms at the start of the most recent epi-
sode of diverticulitis: left lower quadrant pain, fever, altered bowel
habit (diarrhoea, constipation, passage of mucus, or urgency) and
systemic signs (nausea, lethargy), (5) C-reactive protein (CRP)
exceeded the upper limit of normal (ULN) or leucocytosis (>10 000/
mm3) at the start of the most recent episode.
Patients with chronic inflammatory bowel disease (eg, Crohn’s
disease or ulcerative colitis) were excluded. Additional exclusion cri-
teria included complicated diverticulitis (diverticulitis with associated
abscess, fistula, obstruction or perforation), right-sided diverticulitis,
previous colonic surgery, symptomatic organic disease of the GI
tract, active colorectal cancer or history of colorectal cancer, active
malignancy other than colorectal cancer or treatment with
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anticancer drugs during the previous 5 years, haemorrhagic diathe-
sis, active peptic ulcer disease, local intestinal infection, asthma
without careful medical monitoring, abnormal hepatic function or
liver cirrhosis, abnormal renal function, severe co-morbidity and/or
immobility and known intolerance/hypersensitivity/resistance to
study drug or drugs of similar chemical structure. Patients who had
received mesalazine-containing drugs, glucocorticosteroids, opioid
analgesics, laxatives, antidiarrhoeals, immunosuppressants or non-
steroidal anti-inflammatory drugs after the most recent episode
were also excluded.
2.3 | Intervention
Randomisation was performed by means of a computer-generated
randomisation list, using randomly permuted blocks. Product assign-
ment to each patient was undertaken according to this list. In SAG-
37, patients were randomly assigned in a 1:1 ratio to receive mesala-
zine 3.0 g once daily (Salofalk granules, Dr. Falk Pharma GmbH, Frei-
burg, Germany) or placebo over a period of 48 weeks. In SAG-51,
patients were randomised to mesalazine 1.5 g once daily (Salofalk
granules, arm A), mesalazine 3.0 g once daily (Salofalk granules, arm
B) or placebo (arm C) for 96 weeks. The appearance and size of the
placebo treatments were indistinguishable from the active mesala-
zine treatments and both patients and investigator were unaware of
the treatment assignment.
2.4 | Evaluation
The SAG-37 trial included six study visits, and SAG-51 included
12 visits. At baseline and the final visit, demographic data and
total symptom score of Patient Health Questionnaire 15 (PHQ-
15)21 were assessed and body weight was recorded. Laboratory
monitoring at all visits included CRP, leucocyte count and stool
examination. Patients in whom faecal culture was positive for
pathogenic microorganisms were withdrawn from the study. Total
colonoscopy or sigmoidoscopy and biopsy were performed a mini-
mum of 6 weeks after the acute index episode of diverticulitis,
but were to be postponed if the episode was followed by another
acute attack.
2.5 | Study endpoints
The primary endpoint was the proportion of patients who remained
free of diverticulitis recurrence over 48 weeks (SAG-37 and SAG-51)
or 96 weeks (SAG-51). Recurrence of acute diverticulitis was based
on the same diagnostic criteria as the prior episodes being defined
as CRP >ULN or leucocytosis and presence of diverticulitis-like clini-
cal signs plus typical findings on CT scan or ultrasonography (see
above, same criteria for CT and ultrasonography used as for inclu-
sion). As defined in the statistical analysis plan, the primary endpoint
was analysed in subpopulations of patients stratified according to
the number of diverticulitis episodes in the year prior to study entry
(1 or >1) and CRP at study entry (>ULN or ≤ULN). Secondary
endpoints for both studies included the time to recurrence; changes
of erythrocyte sedimentation rate (ESR), CRP level and leucocytosis;
occurrence of diverticulitis-associated fever; percentage of days with
left lower quadrant pain; percentage of days with solid stools, soft
or solid stools, diarrhoea (>3 stools per day) or watery stools; aver-
age number of stools per week; use of spasmolytics; use of anal-
gesics; and total symptom score of PHQ-15 (regardless of missing
answers). Adverse events were recorded throughout the whole study
period.
2.6 | Statistical analysis
The safety population included all randomised patients who received
≥1 dose of study medication. Frequency of adverse events was
stratified by treatment (mesalazine vs placebo). The intent-to-treat
(ITT) population included all randomised patients who received ≥1
dose of study medication and who had a documented attack of
diverticulitis within 6 months prior to study entry. The per protocol
(PP) population included all ITT patients who met all eligibility crite-
ria and had no major protocol deviations. To avoid that patients
with termination due to stopping of the study would be analysed as
patients with recurrence of diverticulitis, two modified versions of
both the ITT and PP analysis set were defined. These modified ver-
sions of the ITT and PP analysis set were subsets of the ITT and PP
analysis set excluding patients who terminated the study due to
stopping of the study before week 48 and week 96, respectively
(Figure 1).
The adaptive designs of the studies, planned interim analyses
and the stopping rules are described in the Data S1. In brief, the
planned interim analysis of study SAG-37, based on 133 ITT
patients, was inconclusive and the Independent Data Monitoring
Committee recommended an additional interim analysis after recruit-
ment of another 100 patients based on a recalculated sample size.
The second interim analysis (233 ITT patients) again proved incon-
clusive and recruitment was stopped, at which point 342 patients
had been recruited. Having the results of SAG-37 as well as negative
results published in the same indication for another mesalazine for-
mulation (press release, Shire, March 30, 2012) the interim analysis
for SAG-51 was brought forward and a rule for stopping the study
due to futility (nonbinding) was introduced. Interim analysis was per-
formed based on 180 ITT patients, and superiority of the mesalazine
groups vs placebo was not shown, leading to the study being
stopped in accordance with the pre-defined study discontinuation
rules.
Confirmatory hypothesis testing at the interim analyses and the
final analyses was based on the inverse normal method of combin-
ing P-values from each stage, using the normal approximation test
for comparing two rates. To estimate the treatment effect, differ-
ences between the proportions of recurrence-free patients were
calculated with the corresponding two-sided 97.5% repeated confi-
dence interval (CI) values. Fisher’s exact test, two-sided, was used
to calculate an unadjusted P-value for the overall comparison of
proportions of recurrence-free patients between treatment groups.
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The unadjusted P-value does not take into account the recursive
design and has to be interpreted in the exploratory sense. To anal-
yse the time to recurrence, a time-to-event analysis was performed
for the event “recurrence of diverticulitis” including calculation of
hazard ratio and corresponding 95% confidence interval if
appropriate. All other analyses were exploratory. The statistical
design, the sample size calculation and statistical analysis were per-
formed with ADDPLAN 6, licensed by ADDPLAN GmbH, an ICON
company, Cologne, Germany, and using the software package SAS
version 9.1 or higher (SAS Institute, Cary, NC, USA).
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Patient did not take any 
study medication.
Excluded n=4
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* To avoid that patients with termination due to stopping of the study would be analysed as patients with recurrence of diverticulitis,
modified subsets of the ITT and PP analysis set were used that exclude patients who terminated the study due to stopping of the
study before week 48 and week 96, respectively.
F IGURE 1 Patient disposition (ITT and PP population)
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3 | RESULTS
3.1 | Patient population
In total, 345 patients were randomised in the SAG-37 trial (171 mesa-
lazine 3.0 g once daily, 174 placebo). Three patients did not receive
any study medication such that the safety population comprised 342
patients (170 mesalazine 3.0 g once daily, 172 placebo) (Figure 1A).
Of these, 247 (72%) completed the 48-week study. Lack of efficacy
was the most frequent reason for discontinuation (Figure S1A). The
most recent episode of diverticulitis was >6 months prior to study
entry in nine patients in SAG-37, so the ITT population included 333
patients (165 mesalazine 3.0 g once daily, 168 placebo) (Figure 1A). In
the SAG-51 study, 330 were randomised and treated and formed the
safety population (125 mesalazine 1.5 g once daily [arm A], 92 mesala-
zine 3.0 g once daily [arm B], 113 placebo [arm C]) (Figure 1B, Fig-
ure S1B). In six patients, the most recent episode of diverticulitis was
>6 months earlier, so the ITT population included 324 patients (123,
90 and 111 patients respectively). To avoid that patients with termina-
tion due to stopping of the study would be analysed as patients with
recurrence of diverticulitis, modified subsets of the ITT and PP analysis
set were defined that excluded patients who terminated the study due
to stopping of the study before week 48 and week 96 respectively. In
SAG-51, 243 patients completed the week 48 of the study or with-
drew early for reasons other than the early study cessation, which
occurred before week 48, and 161 patients completed the week 96
visit or withdrew early for reasons other than the early stopping of the
study. The proportion of patients who discontinued prematurely in the
SAG-37 trial was 31.2% in the mesalazine group vs 24.4% in the pla-
cebo group; in SAG-51 the proportions were 97.6%, 94.6%, 89.4% in
arms A, B and C, respectively (primary reason: study cessation after
interim analysis).
The demographics and clinical characteristics of the study groups
were well balanced across study arms in both trials (Table S1). The
number of previous episodes of diverticulitis and CRP levels were
comparable. The mean (SD) time since the start of the most recent
episode of diverticulitis was 84 (42) days in the mesalazine arm and
90 (53) days in the placebo arm in SAG-37 (overall median 75 days,
range 3-334 days). In SAG-51, the mean (SD) time since the start of
the most recent episode was 93 (44) days in the 1.5 g mesalazine
arm, 87 (44) in the 3.0 g mesalazine arm and 88 (45) days in the pla-
cebo arm (overall median 78 days, range 5-223 days).
3.2 | Efficacy: primary endpoint
In SAG-37, the primary endpoint of freedom from diverticulitis
recurrence over 48 weeks was similar for the patients in the mesala-
zine 3.0 g group and the placebo group (67.9% vs 74.4%; P=.226;
ITT population) (Table 1; Figure 2A). Recurrence by week 48 was
documented in 18.8% (31/165) and 11.9% (20/168) of patients in
the mesalazine and placebo groups, respectively (Table S2), with
recurrence-free withdrawal in 13.3% and 13.7% of patients. In the
per protocol population, the proportions of recurrence-free patients
were 78.9% (105/133) and 89.8% (123/137) (P=.018), respectively.
In SAG-51, 46.0% of patients treated with mesalazine 1.5 g,
52.0% of patients given mesalazine 3.0 g and 58.0% of placebo-trea-
ted patients remained free from diverticulitis recurrence over the
first 48 weeks (P=.860 for mesalazine 3.0 g vs placebo; modified
ITT) (Table 1; Figure 2B). Recurrence was observed in 17.2% (15/
87), 20.0% (15/75), and 21.0% (17/81) of patients, respectively













Percentage of patients free of diverticulitis recurrence
Over 48 weeks (n/N) 67.9 (112/165)c 74.4 (125/168) 46.0 (40/87) 52.0 (39/75)d 58.0 (47/81)
Over 96 weeks (n/N) NA NA 6.9 (4/58) 9.8 (5/51)e 23.1 (12/52)
Subpopulation analysis
Recurrence-free over 48 weeks
Number of diverticulitis episodes <1 year before study entry
1, n/N (%) 61/92 (66.3) 71/91 (78.0) 26/47 (55.3) 21/38 (55.3) 20/33 (60.6)
>1, n/N (%) 51/73 (69.9) 54/76 (71.1) 14/40 (35.0) 18/37 (48.6) 27/48 (56.3)
CRP at study entry
CRP >ULN, n/N (%) 39/63 (61.9) 52/70 (74.3) 6/23 (26.1) 10/20 (50.0) 15/26 (57.7)
CRP ≤ULN, n/N (%) 73/102 (71.6) 71/96 (74.0) 33/63 (52.4) 29/55 (52.7) 32/55 (58.2)
NA, not applicable.
aPatients with completion of week 48 or study termination for another reason than “stop of the whole study” before week 48.
bPatients with completion of week 96 or study termination for another reason than “stop of the whole study” before week 96.
cFisher’s exact test: 48 week mesalazine 3.0 g vs Placebo (SAG-37): P=.226.
dFisher’s exact test: 48 week mesalazine 3.0 g vs Placebo (SAG-51): P=.520.
eFisher’s exact test: 96 week mesalazine 3.0 g vs Placebo (SAG-51): P=.110.
286 | KRUIS ET AL.
(Table S2), with recurrence-free withdrawal in 35.6%, 25.3% and
18.5% (recurrence was not evaluable in five patients). Of the 161
patients who were followed to week 96, the proportion who
remained recurrence-free throughout the 96-week treatment
was 6.9% in the mesalazine 1.5 g group, 9.8% in the mesalazine
3.0 g group, and 23.1% in the placebo arm (P=.980 for mesalazine
3.0 g vs placebo; modified ITT; Table 1). Recurrence was observed
in 27.6% (16/58), 33.3% (17/51), and 38.5% (20/52) of patients,
respectively.
3.3 | Secondary efficacy endpoints
SAG-37 showed no significant difference in the time to diverticulitis
recurrence between treatment groups (Table S2): mean (SD) 136
(100) days in the mesalazine group (n=31) vs 141 (103) days in the
placebo group (n=20); hazard ratio (95% CI) 0.60 (0.34, 1.05) (log-
rank P=.069). Similar results were obtained in the SAG-51 trial,
where the mean (SD) time to recurrence was 116 (134) days in the
mesalazine 1.5 g once daily group (n=16), 191 (125) days in the
mesalazine 3.0 g once daily group (n=17), and 147 (162) days in
the placebo group (n=20); hazard ratio (95% CI) 0.74 (0.38, 1.43)
(log-rank P=.369) for mesalazine 1.5 g once daily vs placebo and
1.02 (0.53, 1.94) (log-rank P=.957) for mesalazine 3.0 g once daily vs
placebo (Table S2).
Furthermore, there were no relevant differences nor any positive
effects of mesalazine in either the SAG-37 or SAG-51 study regard-
ing other efficacy endpoints, including the results of ESR, CRP and
leucocytosis at baseline and week 48, recurrence-associated fever or
leucocytosis, the mean percentage of days with any left lower quad-
rant pain or stools of different consistency, mean number of stools
per week, and use of spasmolytics or analgesics (Table S2). Consis-
tently, the assessment of symptom severity with the Patient Health
Questionnaire 15 (PHQ-15) did not show any difference between
the mesalazine treatment and placebo groups on symptom severity
(Table S2).
3.4 | Subpopulation analyses
The proportion of patients in SAG-37 and SAG-51 with one, two,
three or more than three episodes of diverticulitis in the year prior
to study entry was similar between treatment groups (Table S1).
Treatment with mesalazine showed no advantage for diverticulitis
recurrence vs placebo in the subpopulations with one or more than














































F IGURE 2 Proportion of patients free
of diverticulitis recurrence over 48 weeks
(SAG-37: ITT population; SAG-51: modified
ITT population)
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effect was observed when patients were stratified according to CRP
at study entry (Table 1).
3.5 | Recurrence of diverticulitis
Overall, 71.2% (237/333) of patients in SAG-37 and 51.9% (126/
243) of patients in SAG-51 remained free from diverticulitis recur-
rence by week 48. In SAG-51, 13.0% (21/161) of patients were
recurrence-free until week 96. The mean recurrence rate of all treat-
ment arms of both studies was 17.0% (98/576) for 48 weeks and
32.9% (53/161) for 96 weeks. A pooled post hoc subgroup analysis
of the combined placebo arms from the two studies showed the risk
of recurrence was lower in patients with only one diverticulitis epi-
sode in the year prior to study entry compared to >1 episode, with a
nonsignificant trend to higher risk for recurrence in patients aged
less than 60 years vs ≥60 years (Table 2). Other factors, including
the number of diverticula at baseline, showed no association with
risk for recurrence (Table 2). Increased CRP (>ULN) during the most
recent diverticulitis episode was predictive for recurrence, but since
this was an inclusion criterion, the virtual absence of a comparator
group (CRP ≤ULN) makes the analysis unreliable. Consistent with
reported cases of CT-diagnosed acute diverticulitis,22 less than 50%
of the patients with recurrent diverticulitis showed recurrence-asso-
ciated fever (26%; 25/98) and/or leucocytosis (41%; 40/98).
3.6 | Safety
Overall, 85% (327/387) of participants on mesalazine and 79% (225/
285) of participants on placebo reported adverse events irrespective
of causality, predominantly infections and gastrointestinal disorders
(Table S3). 14% (55/387) of patients on mesalazine and 10% (29/
285) of patients on placebo experienced serious adverse events.
Two serious adverse events (agranulocytosis, colectomy due to
diverticulitis) were considered by the investigator to be related to
intake of mesalazine. Adverse events led to discontinuation of the
study drug in 25% (97/387) of the mesalazine group and 18% (51/
285) of the placebo group of which the majority were cases of
diverticulitis (71 on mesalazine, 38 on placebo).
TABLE 2 Post hoc subgroup analysis of the combined placebo arms from SAG-37 (n=145) and SAG-51 (n=66) for risk factors for





N=39 Odds ratio 95% CI P-value
Number of previous diverticulitis episodes, n (%)
1 91 (52.9) 12 (30.8) 0.40 0.19-0.83 .014
>1 81 (47.1) 27 (69.2)
CRP at most recent episode, n (%)
>ULN 136 (79.1) 31 (79.5) 6.58 1.05-41.07 .044
≤ULN 2 (1.2) 3 (7.7)
Age at baseline, n (%)
<60 94 (54.7) 28 (71.8) 2.11 0.99-4.51 .054
≥60 78 (45.3) 11 (28.2)
Gender, n (%)
Male 73 (42.4) 21 (53.8) 0.63 0.31-1.27 .198
Female 99 (57.6) 18 (46.2)
Body mass index at baseline, kg/m2, n (%)
<30 120 (69.8) 24 (61.5) 0.69 0.34-1.43 .320
≥30 52 (30.2) 15 (38.5)
Numbers of diverticula at baseline, n (%)
≤5 19 (11.0) 3 (7.7) 0.65 0.18-2.39 .519
>5 95 (55.2) 23 (59.0)
Concomitant treatment with psyllium, n (%)
Yes 13 (7.6) 2 (5.1) 0.66 0.14-3.06 .597
No 159 (92.4) 37 (94.9)
Time since most recent attack of uncomplicated diverticulitis, n (%)
≤6 weeks 23 (13.4) 6 (15.4) 1.15a 0.41-3.26a .752a
>6 weeks and ≤12 weeks 73 (42.4) 16 (41.0) 0.97a 0.46-2.06a .786a
>12 weeks 75 (43.6) 17 (43.6)
Bold P-values: statistically significant (P <.05)
avs >12 weeks.
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4 | DISCUSSION
These two randomised, double-blind SAG-37 and SAG-51 trials
showed no benefit of mesalazine in reducing the risk of recurrent
acute diverticulitis. The primary endpoint, the proportion of recur-
rence-free patients during 48 or 96 weeks of treatment, was compa-
rable for patients treated with mesalazine (1.5 g/d or 3.0 g/d) or
placebo. In addition, there was no significant difference between the
mesalazine and placebo groups with respect to the time to recur-
rence, any of the other secondary outcomes related to diverticulitis-
associated symptoms or the markers for inflammation or infection.
These findings concur with those of two recent large, placebo-
controlled, double-blind, randomised trials (PREVENT 1 and 2), which
failed to show an effect of mesalazine (1.2, 2.4 or 4.8 g/d) in pre-
venting diverticulitis recurrence vs placebo.18 In PREVENT 1 and 2,
the recurrence-free rate varied between 53% and 69% in the mesa-
lazine treatment groups, compared to 65% and 69% in the placebo
arms. The presence of abdominal pain was also similar between
study arms. The authors concluded that mesalazine should not be
used for prevention of recurrent diverticulitis. These trials were criti-
cised to only use CT data as the diagnostic tool for recurrent diverti-
culitis, while ignoring global symptoms.19 In contrast, we included in
our primary endpoint for diagnosing prior and recurrent episodes
next to imaging criteria (CT or ultrasonography) also diverticulitis-like
clinical symptoms and increased inflammation markers. However,
also the inclusion of more global symptoms in our study led to the
same conclusion, ie, mesalazine does not prevent recurrent acute
diverticulitis.
Previously, several randomised trials concluded that mesalazine is
effective in the treatment of SUDD.9-15 However, SUDD and acute
diverticulitis are different entities. SUDD, a controversial diagnosis,
also sometimes confusingly referred to as symptomatic diverticulosis,
is defined only by abdominal symptoms and not by the presence of
objective signs of inflammation such as increased CRP,3,23 or typical
findings by cross-sectional imaging. In contrast, acute diverticulitis
has clear diagnostic criteria based on clinical symptoms and objective
confirmation of active inflammation. Furthermore, differential diag-
nosis between SUDD and IBS is particularly very difficult and recent
reports suggesting some benefits of mesalazine in treating subgroups
of IBS patients may further complicate the interpretation of these
studies.24,25 Nevertheless, treatment with mesalazine reduced pain
associated with SUDD better than placebo11 and appeared to be
better than placebo for maintaining remission of SUDD.13 In the
light of these results, some studies also looked at the role of mesala-
zine in preventing recurrence of acute diverticulitis.16,17 In the study
by Parente et al., 800 mg mesalazine was given twice daily for
10 days every month and compared to placebo.16 Both the first epi-
sode of acute diverticulitis (<12 months) as well as recurrence were
diagnosed similarly to our study with the presence of abdominal
pain, associated with leucocytosis and/or fever and confirmation by
CT and/or ultrasonography. Consistent with our data, mesalazine did
not reduce the risk of recurrence but induced significant improve-
ment of patients’ physical conditions and significantly lowered the
additional consumption of other gastrointestinal drugs. While we
could confirm that the rate of recurrence was not affected by mesa-
lazine treatment, we could not detect any effect in patient’s health
assessment (PHQ-15). Furthermore, as we did not see any difference
in the consumption of analgesics or spasmolytics between the differ-
ent treatment arms, we could not confirm a reduction in pain in
acute diverticulitis by mesalazine as it has been reported for the
treatment of SUDD.11
Stollman et al.17 treated in the DIVA study patients with clinical
diagnosis of acute diverticulitis confirmed by CT with mesalazine for
12 weeks and followed them for 9 months. Although not statistically
significant for the prevention of diverticulitis recurrence, the DIVA
study observed a decrease in mean global symptom score for mesa-
lazine compared to placebo. However, in contrast to our study or
the PREVENT trials, the recurrent episode was not assessed by CT
or ultrasonography. Whether mesalazine may effect global symptoms
is subject to broader discussions,19 but our trials did not show any
effect of mesalazine on symptoms compared to placebo. Neverthe-
less, it should be noted that the DIVA and our trials used different
approaches to record symptoms, with the DIVA trial applying a more
rigorous global symptom score, but with evaluation after 12 weeks
of treatment only.
Post hoc subpopulation analyses in placebo-treated patients
showed that more than one prior episode of diverticulitis, compared
to a single episode, was associated with a higher risk for recurrence.
The degree of CRP elevation during the previous episode of diverti-
culitis showed no association with risk for recurrence, but this is not
unexpected given that the median time since the last episode was
75-78 days, and fewer than 40% of patients in either study pre-
sented with elevated CRP at baseline. Overall recurrence-free rates
seen in both trials were different (71.2% and 51.9%). A reason for
the higher rate in SAG-37 may be that relapses were diagnosed by
ultrasound or CT, while in SAG-51 imaging by CT was mandatory;
the latter could result in earlier admission to hospital. In addition,
the inflammation of diverticula and the peri-colonic area was only in
SAG-51 explicitly assessed. In SAG-37, however, the assessment of
only colonic wall thickening without explicit assessing of inflamma-
tory signs might have also overestimated the incidence of true acute
diverticulitis and thus, attributed to the higher reported recurrence
rate. Overestimation as well as underestimation for the diagnosis of
diverticulitis has been demonstrated using CT.26,27
Comparison of our safety data for mesalazine in the prevention
of recurrent acute diverticulitis with the cumulative experience in
inflammatory bowel disease did not raise any new safety concern
for the patient population under investigation. Frequency of drug-
related GI disorders was identical in both treatment arms. Mesala-
zine was tolerated well in patients who had suffered from left-sided
uncomplicated acute diverticulitis with a very low rate of drug-
related serious adverse events. However, one patient showed seri-
ous agranulocytosis with sore throat as a typical initial symptom,
which is a well-known and very rare side effect of mesalazine. The
patient withdrew mesalazine and was treated with filgrastim upon
hospital admission. The patient fully recovered and the
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agranulocytosis was resolved. Diverticulitis as the most common
safety reason for drug interruption clearly reflects the negative
results of efficacy in both trials. However, taking into account the
very rare, but serious side effect of agranulocytosis reported in one
patient treated with mesalazine, our study emphasises the impor-
tance to prescribe even drugs with a very good safety profile such
as mesalazine only for indications in which efficacy is proven.
Both trials as well as PREVENT 1 and 2 provide prospective data
on true recurrence rates presenting evidence that recurrence is a
rather frequent event within 1-2 years after a previous attack. These
data are useful for planning of future clinical trials evaluating
whether other therapies prevent recurrent acute diverticulitis. We
observed recurrence rates of 17% and 33% during 48 and 96 weeks
of treatment respectively. The PREVENT trials generated similar
recurrence rates of 27% each for patients who completed the study
to week 104,18 a value comparable to our observation.
In conclusion, our data show that mesalazine was not superior to
placebo to prevent recurrence of acute diverticulitis. Whether the
anti-inflammatory effects of mesalazine are too weak to prevent
recurrence or whether the pathophysiology of acute diverticulitis
cannot be compared to chronic inflammatory conditions such as
ulcerative colitis remains highly speculative.
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